Medical Management of Growth Hormone-Secreting Pituitary Adenomas
dc.contributor.author | Racine, Michael S. | en_US |
dc.contributor.author | Barkan, Ariel L. | en_US |
dc.date.accessioned | 2006-09-11T19:03:55Z | |
dc.date.available | 2006-09-11T19:03:55Z | |
dc.date.issued | 2002-06 | en_US |
dc.identifier.citation | Racine, Michael S.; Barkan, Ariel L.; (2002). "Medical Management of Growth Hormone-Secreting Pituitary Adenomas." Pituitary 5(2): 67-76. <http://hdl.handle.net/2027.42/47513> | en_US |
dc.identifier.issn | 1386-341X | en_US |
dc.identifier.issn | 1573-7403 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/47513 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12675503&dopt=citation | en_US |
dc.description.abstract | The primary treatment of acromegaly remains transsphenoidal adenomectomy, yet the tissue overgrowth of acromegaly often progresses following surgery, and responds to radiotherapy only after significant delay. Persistently elevated serum growth hormone (GH) and insulin-like growth factor-I (IGF-I) concentrations can be normalized in about half of post-surgery acromegalics using the pharmacologic alternatives presently available, the dopamine agonists (DA) and somatostatin (SST) analogs. Cabergoline, the most efficacious DA, normalizes IGF-I in approximately 37% of patients, whereas the long-acting SST analogs, Octreotide LAR and Lanreotide SR, do so in 66%. Significant tumor shrinkage may be attained with SST analogs in particular, and when necessary, the primary medical treatment of acromegaly may be successfully addressed with this class of drugs. Greatly enhanced efficacy is expected from the GH receptor antagonist pegvisomant, which is nearing market availability and will enable the normalization of serum IGF-I in virtually all patients treated. We review here the pharmacologic treatments of excessive GH secretion. | en_US |
dc.format.extent | 106299 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers; Springer Science+Business Media | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Diabetes | en_US |
dc.subject.other | Neurosurgery | en_US |
dc.subject.other | Pituitary Adenoma | en_US |
dc.subject.other | Acromegaly | en_US |
dc.subject.other | Dopamine Agonist | en_US |
dc.subject.other | Somatostatin Analog | en_US |
dc.subject.other | Pegvisomant | en_US |
dc.title | Medical Management of Growth Hormone-Secreting Pituitary Adenomas | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Endocrinology and Metabolism, University of Michigan Medical Center, 3920 Taubman Center, Box 0354, Ann Arbor, Michigan, 48109-0354, USA | en_US |
dc.contributor.affiliationum | Division of Endocrinology and Metabolism, University of Michigan Medical Center, 3920 Taubman Center, Box 0354, Ann Arbor, Michigan, 48109-0354, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 12675503 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/47513/1/11102_2004_Article_5115783.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1023/A:1022356313153 | en_US |
dc.identifier.source | Pituitary | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.